INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $921,169 | -24.6% | 219,326 | 0.0% | 0.21% | -26.2% |
| Q2 2023 | $1,221,646 | -2.8% | 219,326 | 0.0% | 0.29% | -11.9% |
| Q1 2023 | $1,256,738 | +445.7% | 219,326 | 0.0% | 0.33% | +391.0% |
| Q4 2022 | $230,292 | +23.8% | 219,326 | +216.4% | 0.07% | +26.4% |
| Q3 2022 | $186,000 | -43.8% | 69,326 | 0.0% | 0.05% | -44.8% |
| Q2 2022 | $331,000 | +386.8% | 69,326 | +314.5% | 0.10% | +540.0% |
| Q1 2022 | $68,000 | -40.4% | 16,726 | 0.0% | 0.02% | -34.8% |
| Q4 2021 | $114,000 | -41.2% | 16,726 | 0.0% | 0.02% | -45.2% |
| Q3 2021 | $194,000 | -31.9% | 16,726 | 0.0% | 0.04% | -30.0% |
| Q2 2021 | $285,000 | -13.9% | 16,726 | 0.0% | 0.06% | -18.9% |
| Q1 2021 | $331,000 | -4.1% | 16,726 | 0.0% | 0.07% | -11.9% |
| Q4 2020 | $345,000 | -21.6% | 16,726 | 0.0% | 0.08% | -17.6% |
| Q3 2020 | $440,000 | – | 16,726 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 1,009,117 | $26,529,000 | 9.44% |
| YALE UNIVERSITY | 113,502 | $2,984,000 | 9.13% |
| Sofinnova Investments, Inc. | 2,028,308 | $53,324,000 | 3.95% |
| Novo Holdings A/S | 2,569,379 | $67,549,000 | 3.35% |
| NEA Management Company, LLC | 2,444,379 | $64,263,000 | 2.72% |
| RA Capital Management | 2,003,653 | $52,676,000 | 0.96% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,150,299 | $30,241,000 | 0.74% |
| Rock Springs Capital Management LP | 879,954 | $23,134,000 | 0.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 196,411 | $5,164,000 | 0.51% |
| Orbimed Advisors | 400,400 | $10,527,000 | 0.13% |